Pfizer's 6.3% dividend yield faces risk as payouts exceed free cash flow, raising sustainability concerns.

Pfizer's dividend yield stands at 6.3%, attractive to retirement investors, but the company paid more in dividends than it generated in free cash flow in 2025, signaling potential risk. The payout ratio based on GAAP earnings exceeds 100%, and Pfizer's debt has increased while liquid assets have declined due to acquisitions. Although Pfizer has raised dividends for 16 consecutive years since 2010, growth is modest and the company cut dividends in 2009 during the financial crisis. Management focuses on growth and pipeline development, with no share buybacks planned in 2026 to preserve cash. The upcoming Q1 2026 earnings call will be crucial to assess dividend sustainability, especially if free cash flow stabilizes. Investors should be cautious about the high yield given the payout risks and financial pressures.